Tue Oct 30, 2007 - Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced that it has entered the final stages of compound selection for two of the most rapidly growing therapeutic indications, asthma and type 2 diabetes... Forbes Medi-Tech's Press Release -
Blog Archive
-
▼
2007
(90)
-
▼
November
(14)
- Vectura and Sosei, Phase II Studies of QVA149 for ...
- Aeolus Pharmaceuticals, Pipeline, COPD
- Amira Pharmaceuticals, Initiates Clinical Studies ...
- NicOx, TOPIGEN initiates phase 2 proof of concept ...
- SPO Medical, New Oximetry Devices for European Mar...
- Advanced Life Sciences, Cethromycin, Second Pivota...
- Pharmion's Amrubicin, Results Compared to Standard...
- MAP Pharmaceuticals, Phase 2a Clinical Trial of Co...
- Gilead and LG Life Sciences, Global License Agreem...
- Æterna Zentaris, Multi-Center Phase 2 Trial with P...
- Alfacell's ONCONASE, Radiation Sensitizer for Lung...
- Nabi Biopharmaceuticals, NicVAX(R) , Significant R...
- Forbes Medi-Tech, Final Steps in Compound Selecti...
- Theravance, Initiation of Phase 2 Clinical Program...
-
▼
November
(14)
Nov 6, 2007
Forbes Medi-Tech, Final Steps in Compound Selection for Asthma
Tue Oct 30, 2007 - Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced that it has entered the final stages of compound selection for two of the most rapidly growing therapeutic indications, asthma and type 2 diabetes... Forbes Medi-Tech's Press Release -
